Merck & Company, Inc. (MRK) will make a research milestone payment of $9 million to Ginkgo Bioworks Holdings following the completion of the first milestone in their partnership.
Argus cut its price target for Merck & Company, Inc. (MRK) from $140 to $125. The stock has an average 'outperform' rating, with targets ranging from $100 to $155, according to Capital IQ analysts.